#QuolipsInc

Quolips, Inc. announced that it has obtained conditional and time-limited manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for the human (allogeneic) iPS cell-derived cardiomyocyte sheet "Reheart" on March 6, 2026.

The Pharmaceuticals and Medical Devices Agency panel has determined that the human (allogeneic) iPS cell-derived cardiomyocyte sheet IPSOC-1 can be approved with conditions and time limitations, and formal approval by the Ministry of Health, Labour and Welfare is expected.